手机扫码接着看

topnftearninggames| Shenzhen Ruijie: Demand for services such as testing and identification is accelerating and the company has actively followed up on relevant policies

Author:editor|Category:Science

News summary

[Shenzhen Ruijietopnftearninggames: Demand for services such as testing and identification is accelerating and the company has actively followed up on relevant policies] Securities Times e Company NewstopnftearninggamesShenzhen Ruijie (300977) stated on the interactive platform that the company's main business is third-party evaluation, project management and engineering management information technology services, inspectiontopnftearninggames.topnftearninggames..

topnftearninggames| Shenzhen Ruijie: Demand for services such as testing and identification is accelerating and the company has actively followed up on relevant policies

Newsletter text

[Shenzhen Ruijie: Demand for services such as testing and appraisal is accelerating and the company has actively followed up on relevant policies] Securities Times e Company News, Shenzhen Ruijie (300977) stated on the interactive platform that the company's main business is third-party evaluation, project management and collaborative business represented by engineering management information technology services, testing and appraisal, testing and appraisal is an important direction of the company's strategic layout. As the scale of existing housing management and services becomes larger and larger, residents 'demand for quality living throughout the life cycle of "good houses" and "good communities" is increasing, and the demand for services such as third-party evaluation, project management, and testing and identification is accelerating. At present, the company has actively followed up on relevant policies, and the specific impact cannot be accurately judged.

27 05

2024-05-27 04:13:40

浏览14
Back to
Category
Back to
Homepage
mentalslot| South Gobi (01878.HK): A total of 216,600 shares were issued under the equity award plan on May 24 ice36casino| Hengrui Pharmaceutical (600276.SH): Subsidiary SHR-A1921 for injection is expected to be included in the public list of breakthrough treatment varieties